Press Releases ContraFect Corporation

Equities

CFRXQ

US2123264093

Delayed OTC Markets Other stock markets 11:20:31 2024-07-16 am EDT			5-day change	1st Jan Change
0.015 ^USD	-3.23%		-25.74%	-50.00%

May. 03	North American Morning Briefing : Apple, Amgen -2-	DJ
Apr. 26	North American Morning Briefing : Tech Still in -2-	DJ

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ContraFect: Q3 Earnings Snapshot	Nov. 14	AQ
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study	23-10-16	AQ
ContraFect to Present at the ASM/ESCMID Joint Conference on Drug Development	23-09-19	AQ
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370	23-09-18	AQ
ContraFect to Present at the World Anti-Microbial Resistance Congress 2023	23-08-28	AQ
ContraFect : Q2 2023 Investor Presentation	23-08-15	PU
ContraFect: Q2 Earnings Snapshot	23-08-14	AQ
ContraFect Reports Second Quarter 2023 Financial Results and Provides Business Update	23-08-14	AQ
ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 Million	23-06-27	AQ
CONTRAFECT CORP : Submission of Matters to a Vote of Security Holders (form 8-K)	23-06-20	AQ
ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens	23-06-20	AQ
ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023	23-06-08	AQ
CONTRAFECT CORP : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K)	23-05-16	AQ
ContraFect: Q1 Earnings Snapshot	23-05-15	AQ
ContraFect Reports First Quarter 2023 Financial Results and Provides Business Update	23-05-15	AQ
ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee	23-04-26	AQ
ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens	23-04-20	AQ
CONTRAFECT CORP : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)	23-04-18	AQ
ContraFect Announces Multiple Presentations of New Data at the 33rd Annual ECCMID Meeting	23-04-06	AQ
ContraFect Announces Initiation of a Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee	23-04-03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ContraFect Corporation

Equities

CFRXQ

US2123264093

Press Releases

Filters